The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oncolytic Virus Cancer Immunotherapy Market Research Report 2024
Synopsis
Oncolytic virus is a special virus that can beneficially infect and kill cancer cells. These are deployed as part of cancer immunotherapy and work by selectively targeting cancer cells and performing oncolytics. Oncolytic viruses can not only kill cancer cells directly, but also stimulate patients' own anti-tumor immune response.
The global Oncolytic Virus Cancer Immunotherapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The first oncolytic virus immunotherapy was approved in Latvia in 2004 for the treatment of cutaneous melanoma. Inevitable changes in the environment due to human activities are causing various factors, leading to an increase in the incidence of many skin malignancies, including non-melanoma skin cancer. Conventional radiation and chemotherapy known to treat various cancers, including cutaneous melanoma, have a limited therapeutic index and a range of treatment-related side effects.
This report aims to provide a comprehensive presentation of the global market for Oncolytic Virus Cancer Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Virus Cancer Immunotherapy.
Report Scope
The Oncolytic Virus Cancer Immunotherapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncolytic Virus Cancer Immunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncolytic Virus Cancer Immunotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Amgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co., Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
Segment by Type
Monoclonal Antibodies
Checkpoint Inhibitors
Oncoloytic Viral Therapies and Cancer Vaccines
Segment by Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncolytic Virus Cancer Immunotherapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Oncolytic virus is a special virus that can beneficially infect and kill cancer cells. These are deployed as part of cancer immunotherapy and work by selectively targeting cancer cells and performing oncolytics. Oncolytic viruses can not only kill cancer cells directly, but also stimulate patients' own anti-tumor immune response.
The global Oncolytic Virus Cancer Immunotherapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The first oncolytic virus immunotherapy was approved in Latvia in 2004 for the treatment of cutaneous melanoma. Inevitable changes in the environment due to human activities are causing various factors, leading to an increase in the incidence of many skin malignancies, including non-melanoma skin cancer. Conventional radiation and chemotherapy known to treat various cancers, including cutaneous melanoma, have a limited therapeutic index and a range of treatment-related side effects.
This report aims to provide a comprehensive presentation of the global market for Oncolytic Virus Cancer Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Virus Cancer Immunotherapy.
Report Scope
The Oncolytic Virus Cancer Immunotherapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncolytic Virus Cancer Immunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncolytic Virus Cancer Immunotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Amgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co., Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
Segment by Type
Monoclonal Antibodies
Checkpoint Inhibitors
Oncoloytic Viral Therapies and Cancer Vaccines
Segment by Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncolytic Virus Cancer Immunotherapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Checkpoint Inhibitors
1.2.4 Oncoloytic Viral Therapies and Cancer Vaccines
1.3 Market by Application
1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Head and neck Cancer
1.3.8 Ovarian Cancer
1.3.9 Pancreatic Cancer
1.3.10 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncolytic Virus Cancer Immunotherapy Market Perspective (2019-2030)
2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Region
2.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Size by Region (2019-2024)
2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2025-2030)
2.3 Oncolytic Virus Cancer Immunotherapy Market Dynamics
2.3.1 Oncolytic Virus Cancer Immunotherapy Industry Trends
2.3.2 Oncolytic Virus Cancer Immunotherapy Market Drivers
2.3.3 Oncolytic Virus Cancer Immunotherapy Market Challenges
2.3.4 Oncolytic Virus Cancer Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue
3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2019-2024)
3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2019-2024)
3.2 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue
3.4 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio
3.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2023
3.5 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served
3.6 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
3.7 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Type
4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2019-2024)
4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2025-2030)
5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application
5.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Application (2019-2024)
5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)
6.2 North America Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024)
6.4 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)
7.2 Europe Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024)
7.4 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)
8.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)
9.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024)
9.4 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)
10.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction
11.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction
11.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 F Hoffman-La Roche
11.3.1 F Hoffman-La Roche Company Detail
11.3.2 F Hoffman-La Roche Business Overview
11.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction
11.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.3.5 F Hoffman-La Roche Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction
11.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.5.5 Novartis AG Recent Development
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Detail
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction
11.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.6.5 Merck & Co., Inc. Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction
11.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 Biovex
11.8.1 Biovex Company Detail
11.8.2 Biovex Business Overview
11.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction
11.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.8.5 Biovex Recent Development
11.9 Cell Genesys
11.9.1 Cell Genesys Company Detail
11.9.2 Cell Genesys Business Overview
11.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction
11.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.9.5 Cell Genesys Recent Development
11.10 Crusade Laboratories
11.10.1 Crusade Laboratories Company Detail
11.10.2 Crusade Laboratories Business Overview
11.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction
11.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.10.5 Crusade Laboratories Recent Development
11.11 Genelux Corporation
11.11.1 Genelux Corporation Company Detail
11.11.2 Genelux Corporation Business Overview
11.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction
11.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.11.5 Genelux Corporation Recent Development
11.12 Lokon Pharma
11.12.1 Lokon Pharma Company Detail
11.12.2 Lokon Pharma Business Overview
11.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction
11.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.12.5 Lokon Pharma Recent Development
11.13 MultiVir
11.13.1 MultiVir Company Detail
11.13.2 MultiVir Business Overview
11.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction
11.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.13.5 MultiVir Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
